Differential effect of concurrent chemotherapy regimen on clinical outcomes of preoperative chemoradiotherapy for locally advanced rectal cancer
- Authors
- Kim, Eunji; Kim, Kyubo; Oh, Do Hoon; Han, Sae-Won; Kim, Tae-You; Jung, Seung-Yong; Park, Kyu Joo; Kang, Gyeong Hoon; Chie, Eui Kyu
- Issue Date
- Mar-2019
- Publisher
- IMPRIMATUR PUBLICATIONS
- Keywords
- chemoradiotherapy; chemotherapy regimen; neoadjuvant; rectal cancer
- Citation
- JOURNAL OF BUON, v.24, no.2, pp 470 - 478
- Pages
- 9
- Journal Title
- JOURNAL OF BUON
- Volume
- 24
- Number
- 2
- Start Page
- 470
- End Page
- 478
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/44865
- ISSN
- 1107-0625
2241-6293
- Abstract
- Purpose: The purpose of this study was to evaluate the differential effect of chemotherapy regimen in preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer. Methods: The medical records of 279 patients who underwent preoperative CRT followed by surgery for cT3/4 rectal cancer from 2003 to 2010 were retrospectively reviewed. Thirty-four patients were treated with one cycle of i.v. bolus 5-fluorouracil (5-FU) during 1st week (group A), 214 patients with two cycles of i.v. bolus 5-FU during 1st and 5th week (group B), and 31 patients with oral capecitabine on the days with radiotherapy (group C). Propensity score matching was performed between three groups. Results: Median follow-up was 60.1 months. Five-year locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS) and overall survival (OS) rates were 91.2, 83.3, 75.0, and 84.5%, respectively. Thirty-one patients per group were allocated to three groups via propensity score matching. On univariate analysis, concurrent chemotherapy regimen was not a significant prognostic factor for survival outcomes in the matched group analysis (OS, p=0.175; DFS, p=0.481; DMFS, p=0.515; LRFS, p=0.456). In addition, there was no significant difference in the sphincter preserving surgery rate, circumferential resection margin status, and pathologic response between three groups (p=0.441, 1.000, 0.818, respectively). As regards to treatment-related toxicity, 9 patients showed grade 3 neutropenia in group B, while there was no grade 3 or higher toxicity in groups A and C. Conclusion: The concurrent chemotherapy regimen (5-FU #1 vs 5-FU #2 vs capecitabine) did not have a significant effect on treatment outcomes in locally advanced rectal cancer patients receiving neoadjuvant CRT.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/44865)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.